AzTrials
AzTrials

Condition

Children Clinical Trials

Studies of children, matched by condition name and medical subject headings. Start with those open to enrolment.

28,805 registered studies

In numbers

Open to volunteers
4,811
Active
5,808
With results posted
3,388
All registered
28,805

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 4,811
  • Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis

    Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children

    • Not yet recruiting
    • Age: 1 year to 17 years
    • Phase 3

    Recurrent respiratory papillomatosis (RRP) is a rare disease in which wart-like growths caused by human papillomavirus (HPV) types 6 or 11 form in the airway.

    Conditions
    Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis, Papillomavirus Infections
    Trial name
    NCT07901738
    Testing
    Zopapogene imadenovec-drba
    Where
    United States
    Volunteers
    15 people
    Sponsor
    Precigen, Inc
    Can I take part? NCT07901738
  • Preoperative Anxiety Experienced by the Pediatric Patient, Dental Anxiety in Children

    Evaluating Operation Calm With Children, Parents, and Clinicians

    • Recruiting
    • Age: 6 years and older
    • Lifestyle or therapy programme

    Operation Calm is a single-arm, mixed-methods feasibility study evaluating a virtual reality (VR) nature-based mindfulness intervention with children and adolescents aged 6-17 years, parents, and clinicians.

    Conditions
    Preoperative Anxiety Experienced by the Pediatric Patient, Dental Anxiety in Children, Procedural Anxiety
    Trial name
    NCT07694934
    Testing
    Operation Calm EEMCF-VR
    Where
    Canada
    Volunteers
    150 people, healthy volunteers welcome
    Sponsor
    McGill University
    Can I take part? NCT07694934
  • Seasonal Influenza

    A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

    • Recruiting
    • Age: 9 to 17 years
    • Phase 1

    The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).

    Trial name
    NCT07870330
    Testing
    mRNA-1010, Fluarix Trivalent
    Where
    6 sites in United States
    Volunteers
    96 people, healthy volunteers welcome
    Sponsor
    ModernaTX, Inc.
    Can I take part? NCT07870330
  • Physical Fitness, Health

    Effects of the 11 for Health Program on Physical Fitness and Health-Related Outcomes in Schoolchildren

    • Not yet recruiting
    • Age: 10 to 12 years

    This study aims to examine the effects of the 11 for Health program on physical fitness and health-related outcomes in fifth-grade students. The study will use a quasi-experimental pretest-posttest design with a control group.

    Conditions
    Physical Fitness, Health, Body Composition
    Trial name
    NCT07900399
    Testing
    11 for Health Program
    Where
    Turkey (Türkiye)
    Volunteers
    70 people, healthy volunteers welcome
    Sponsor
    Namik Kemal University
    Can I take part? NCT07900399
  • Acquired Brain Injury

    Exercise and Physical Activity in Children With Pediatric Acquired Brain Injury

    • Recruiting
    • Age: 7 to 18 years
    • Lifestyle or therapy programme

    Exercise and physical activity in children with pediatric acquired brain injury

    Trial name
    DIScover_Ped (NCT06804486)
    Testing
    Exercise, Recommendation to Deprescribe
    Where
    Spain
    Volunteers
    25 people
    Sponsor
    Universidade da Coruña
  • Desmoplastic Small Round Cell Tumor, Osteosarcoma

    Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

    • Recruiting
    • Age: 12 to 39 years
    • Phase 2
    • Surgery or procedure

    This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after…

    Conditions
    Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor
    Trial name
    NCT04616560
    Testing
    Biospecimen Collection, Computed Tomography, Echocardiography Test
    Where
    32 sites in United States
    Volunteers
    55 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT04616560
  • Diffuse Intrinsic Pontine Glioma, DIPG

    Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

    • Recruiting
    • Age: 1 year to 26 years
    • Phase 2

    This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG).

    Conditions
    Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor
    Trial name
    NCT07680439
    Testing
    BCB-276
    Where
    6 sites in United States
    Volunteers
    75 people
    Sponsor
    BrainChild Bio, Inc
    Can I take part? NCT07680439
  • Inherited Retinal Degeneration Associated With RPGR Mutations, Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations

    Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents

    • Recruiting
    • Age: Up to 50 years
    • Observational study

    The goals of this observational study are to develop and train artificial intelligence (AI) algorithms using multimodal imaging to identify patients with inherited retinal degeneration (IRD) caused by Retinal Pigment Epithelium…

    Trial name
    MEDIRET (NCT07901907)
    Where
    3 sites in United States, Germany and 1 more
    Volunteers
    4,887 people, healthy volunteers welcome
    Sponsor
    University College, London
    Can I take part? MEDIRET
  • Neuromuscular Blockade, Delayed Emergence From Anesthesia

    Sugammadex Timing and Recovery Profile in Pediatric Adenotonsillectomy

    • Not yet recruiting
    • Age: 2 to 17 years
    • Observational study

    Sugammadex is routinely used to reverse rocuronium-induced neuromuscular blockade in children. In clinical practice, it is given either while the child is still deeply anesthetized or after the anesthetic has lightened.

    Conditions
    Neuromuscular Blockade, Delayed Emergence From Anesthesia, Emergence Agitation
    Trial name
    SUGA-PED (NCT07902193)
    Where
    Turkey (Türkiye)
    Volunteers
    140 people
    Sponsor
    Namik Kemal University
    Can I take part? SUGA-PED
  • Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

    A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Recruiting
    • Age: 5 to 60 years
    • Phase 3
    • Surgery or procedure

    This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients…

    Trial name
    NCT05675410
    Testing
    Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin
    Where
    419 sites in United States, Canada and 1 more
    Volunteers
    1,875 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT05675410

Completed, with results posted

All 2,974
  • Migraine

    Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

    • Completed
    • Age: 6 to 17 years
    • Phase 3
    • Results posted

    This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.

    Trial name
    OASIS(CM) (NCT03832998)
    Testing
    Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
    Where
    101 sites in United States, Belgium and 11 more
    Volunteers
    284 people
    Sponsor
    Amgen
    Can I take part? OASIS(CM)
  • Peanut Allergy

    Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

    • Completed
    • Age: 2 to 5 years
    • Phase 3
    • Results posted

    Open-label, follow-up study for subjects who completed the EPITOPE study.

    Trial name
    EPOPEX (NCT03859700)
    Testing
    DBV712 250 mcg
    Where
    26 sites in United States
    Volunteers
    304 people
    Sponsor
    DBV Technologies
    Can I take part? EPOPEX
  • Pediatric ALL, Child, Hospitalized

    Robot Rehab: AAI With Robot During Inpatient Pediatric Rehab

    • Completed
    • Age: 5 to 18 years
    • Medical device
    • Results posted

    The purpose of this study is to: Aim 1: Evaluate the feasibility [consent and refusal rates, attrition rates, length, and number of completed therapy sessions], and acceptability [interviews with children and guardians, overall…

    Conditions
    Pediatric ALL, Child, Hospitalized, Physical Therapy Modalities, Occupational Therapy
    Trial name
    NCT05275543
    Testing
    Paro Robot
    Where
    United States
    Volunteers
    51 people
    Sponsor
    University of Nebraska
    Can I take part? NCT05275543
  • Acute Lymphoblastic Leukemia, Pediatric, Pediatric Cancer

    Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment

    • Completed
    • Age: 3 to 8 years
    • Lifestyle or therapy programme
    • Results posted

    Music therapy has become a standard palliative care service in many pediatric and adult hospitals; however, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health…

    Trial name
    NCT04400071
    Testing
    Active Music Engagement, Audio Storybooks
    Where
    4 sites in United States
    Volunteers
    192 people
    Sponsor
    Indiana University
    Can I take part? NCT04400071
  • HPV Infection, Hiv

    HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

    • Completed
    • Age: 9 to 26 years
    • Phase 4
    • Results posted

    This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini.

    Conditions
    HPV Infection, Hiv, HPV Vaccine
    Trial name
    NCT04982614
    Testing
    Gardasil ® 9
    Where
    5 sites in Eswatini
    Volunteers
    1,403 people
    Sponsor
    Columbia University
    Can I take part? NCT04982614

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in